Anorexia Clinical Trial
Official title:
Prospective Evaluation of a Year of Therapeutic Impact Sensory Workshops on Body Mass Index in Anorexia Adolescent Mental
In the literature the use of olfactory dimension in the treatment of anorexia has not been verified experimentally. The investigator hypothesize that the therapeutic use of a dietary nature olfactory stimuli in anorexia nervosa promotes food recovery. The team propose a prospective study over a period of 12 months in which we use the Body Mass Index (BMI) as the primary endpoint of the state of anorexia nervosa patients.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | March 2015 |
Est. primary completion date | March 2015 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 11 Years to 18 Years |
Eligibility |
Inclusion Criteria: - Diagnosis of anorexia nervosa according to DMS IV-TR (Diagnostic and Statistical Manual of Mental Disorders) criteria. - Follow Outpatient care or hospitalization - Able to respond to the clinical evaluation questionnaires - Affiliated to the social security system - Consentement Informed of the legal representative and the patient Exclusion Criteria: - Somatic comorbidity associated diabetes, celiac disease, brain tumor. - Intolerance Odors, predisposition to develop asthma and / or respiratory allergies. - Pathologie Chronic of nose and sinus. - Hyposmic Or anosmic. |
Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Fondation Lenval |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Assess the impact of sensory workshops on BMI Body Mass Indexat 6 months and 12 months | The primary endpoint is the M6 and increase maintenance M12 BMI Body Mass Index to Comparaison to baseline and 6 month after and maintenance at month 12 |
No |
|
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT01501396 -
Megestrol Acetate With or Without Mirtazapine in Treating Cancer Patients With Weight Loss or Loss of Appetite
|
Phase 2 | |
Active, not recruiting |
NCT01206335 -
Open Label Study With OHR/AVR118 in Advanced Cancer Patients With Anorexia-Cachexia
|
Phase 2 | |
Completed |
NCT02524301 -
Evaluation of Brain Opioid Receptor Activity in Anorexia Nervosa : a PET [11C]Diprenorphine Study
|
N/A | |
Active, not recruiting |
NCT00488072 -
Effects of Mirtazapine on Appetite in Advanced Cancer Patients
|
Phase 2 | |
Withdrawn |
NCT05039385 -
Exercise Program in Patients With Anorexia Nervosa (ESATRAL)
|
N/A | |
Completed |
NCT03097874 -
Adaptive Treatment for Adolescent Anorexia Nervosa
|
N/A | |
Completed |
NCT00031785 -
Megestrol in Treating Patients Who Are Undergoing Radiation Therapy for Lung Cancer
|
Phase 3 | |
Terminated |
NCT00535015 -
Safety and Efficacy Study of Betamarc to Treat Loss of Weight and Appetite in Non-Small Cell Lung Cancer
|
Phase 2 | |
Terminated |
NCT00558558 -
Haelan and Nutrition in Cancer Patients
|
Phase 2 | |
Completed |
NCT00040885 -
Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05)
|
Phase 3 | |
Completed |
NCT00006799 -
Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck Cancer
|
Phase 3 | |
Active, not recruiting |
NCT03637816 -
Anamorelin Hydrochloride in Reducing Anorexia in Patients With Advanced Non-small Cell Lung Cancer
|
Phase 2/Phase 3 | |
Completed |
NCT04007900 -
Positive Affect Treatment (PAT) to Target Reward Mechanisms in Anorexia Nervosa
|
N/A | |
Completed |
NCT00735540 -
Clinical Diagnosis of Teenagers Admitted to Pediatric Departments
|
N/A | |
Completed |
NCT00046904 -
Etanercept in Treating Cancer-Related Cachexia and Anorexia in Patients With Advanced Cancer
|
Phase 3 | |
Completed |
NCT04803305 -
Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia
|
Phase 1 | |
Completed |
NCT05708404 -
Outpatient Treatment of Severe and Enduring Anorexia Nervosa
|
||
Completed |
NCT03283488 -
Comparison Between Mirtazapine and Megestrol for the Control of Anorexia-cachexia in Cancer Patients in Palliative Care.
|
Phase 2 | |
Recruiting |
NCT05503147 -
Sativex® and Gentamicin for Optimized Pharmagological Treatment in Older Patients (CanPan)
|
Phase 1 | |
Terminated |
NCT01200602 -
Megestrol Acetate in Treating Weight Loss or Anorexia in Young Patients With Malignancies Who Are Undergoing Radiation Therapy and/or Chemotherapy
|
Phase 2 |